home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410p.zip
/
M94A3098.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
36 lines
Document 3098
DOCN M94A3098
TI Laboratory markers of long-term survivors with HIV disease.
DT 9412
AU Knight B; Salvato P; Thompson C; Houston Immuno. Institute, TX.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):154 (abstract no. PB0041). Unique
Identifier : AIDSLINE ICA10/94369477
AB OBJECTIVE: To describe laboratory markers of HIV disease in long-term
survivors. METHODS: 174 HIV-seropositive pts. were evaluated
retrospectively by chart review over a 9-yr. period. 64 pts., HIV+ since
1985 and whose CD4 count remained > 500 after 9 years, were reviewed.
Laboratory markers measured in the 9th year were CD4, CD8 counts, p24
antigen, neopterin, and beta 2 microglobulin. In addition, AZT use was
assessed. RESULTS: 38 pts. were on AZT (mean 4(1-6) yrs), 26 were not on
AZT. Mean (mean) CD4 count at the 9th year was 683 (500-1246), mean CD8
count 1465 (644-2250), mean neopertin level 8 (2-36), and mean beta 2
microglobulin level 3.2 (1.6-5.2). 12 pts. were p24 positive (1 on AZT,
11 not on AZT). There were no significant differences in laboratory
markers between pts. on AZT vs. no AZT except for p24 antigen values.
CONCLUSIONS: Long-term survivors in this study maintained CD4 counts >
500 and high CD8 counts over a 9-year period. Neopterin and beta 2
microglobulin levels remained in the relatively normal range. AZT did
not seem to alter laboratory markers of disease progression. AZT did
have an effect on p24 antigen level but this effect did not transulate
into differences in laboratory markers assessed in this study.
DE beta 2-Microglobulin/ANALYSIS Biological Markers/*BLOOD
Biopterin/ANALOGS & DERIVATIVES/BLOOD Comparative Study CD4-CD8 Ratio
Follow-Up Studies Human HIV Core Protein p24/BLOOD HIV
Seropositivity/*BLOOD/DRUG THERAPY/MORTALITY Predictive Value of Tests
Prognosis Retrospective Studies Survival Rate Time Factors T4
Lymphocytes/*IMMUNOLOGY Zidovudine/THERAPEUTIC USE MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).